U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636928) titled 'Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184' on May 29.
Brief Summary: The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
HIV Infections
Intervention:
DRUG: VH4524184
One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).
DRUG: [14C]VH4524184 microdose
A radiolabelled microdose of [14C]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).
DRUG: [14C]VH4524184
One dose of r...